Hackensack University Medical Center Research Applies a Novel Platform of Dual DNA/RNA Signatures Using Liquid Biopsies for Patients with AML or MDS
Study finds targeted NGS can reliably and efficiently provide in one test enough information on the blood to help refine molecular diagnostic in AML and MDS
Hackensack University Medical Center researchers contributed to a recent Frontiers in Oncology study that examined the use of targeted next generation sequencing (NGS) in detecting chromosomal structural abnormalities or copy number variations (CNVs) in patients with myeloid neoplasms.
Key findings include:
- Liquid biopsy using targeted NGS provides a reliable means of detecting chromosomal structural abnormalities in myeloid neoplasms.
- In certain cases, targeted NGS may reliably and efficiently provide enough information without the need for BM biopsy, given that broad mutations profiling is obtainable through adequate sequencing in the same non-invasive test.
- Results support using liquid biopsy for early diagnosis and monitoring of patients with myeloid neoplasms.
Learn more about cancer care innovations at John Theurer Cancer Center at Hackensack University Medical Center.